STOCK TITAN

Allogene Therapeutics Announces Participation in November Investor Conferences

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotech company focused on developing allogeneic CAR T products for cancer and autoimmune disease, has announced its participation in two major investor conferences in November. The company will present at the Stifel 2024 Healthcare Conference on November 18 at 5:35AM PT and the Jefferies London Healthcare Conference on November 20 at 10:00AM GMT. Webcasts will be available on the company's website for approximately 30 days after the events.

Allogene Therapeutics (Nasdaq: ALLO), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di prodotti CAR T allogenici per il cancro e le malattie autoimmuni, ha annunciato la sua partecipazione a due importanti conferenze per investitori a novembre. L'azienda presenterà alla Stifel 2024 Healthcare Conference il 18 novembre alle 5:35 AM PT e alla Jefferies London Healthcare Conference il 20 novembre alle 10:00 AM GMT. I webcast saranno disponibili sul sito web dell'azienda per circa 30 giorni dopo gli eventi.

Allogene Therapeutics (Nasdaq: ALLO), una empresa biotecnológica en etapa clínica centrada en el desarrollo de productos CAR T alogénicos para el cáncer y enfermedades autoinmunes, ha anunciado su participación en dos importantes conferencias para inversores en noviembre. La empresa presentará en la Stifel 2024 Healthcare Conference el 18 de noviembre a las 5:35 AM PT y en la Jefferies London Healthcare Conference el 20 de noviembre a las 10:00 AM GMT. Las transmisiones web estarán disponibles en el sitio web de la empresa durante aproximadamente 30 días después de los eventos.

Allogene Therapeutics (Nasdaq: ALLO)는 암과 자가면역 질환을 위한 동종 CAR T 제품 개발에 중점을 두고 있는 임상 단계 생명공학 회사로, 11월 두 개의 주요 투자자 회의에 참여할 것이라고 발표했습니다. 이 회사는 Stifel 2024 Healthcare Conference에서 11월 18일 오전 5시 35분 PT에 발표하고, Jefferies London Healthcare Conference에서 11월 20일 오전 10시 GMT에 발표할 예정입니다. 웹캐스트는 행사 후 약 30일 동안 회사 웹사이트에서 제공됩니다.

Allogene Therapeutics (Nasdaq: ALLO), une entreprise de biotechnologie en phase clinique axée sur le développement de produits CAR T allogéniques pour le cancer et les maladies auto-immunes, a annoncé sa participation à deux grandes conférences pour investisseurs en novembre. L'entreprise présentera à la Stifel 2024 Healthcare Conference le 18 novembre à 5h35 PT et à la Jefferies London Healthcare Conference le 20 novembre à 10h00 GMT. Des diffusions web seront disponibles sur le site de l'entreprise pendant environ 30 jours après les événements.

Allogene Therapeutics (Nasdaq: ALLO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von allogenen CAR T-Produkten für Krebs und autoimmune Erkrankungen konzentriert, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im November bekannt gegeben. Das Unternehmen wird am 18. November um 5:35 Uhr PT auf der Stifel 2024 Healthcare Conference und am 20. November um 10:00 Uhr GMT auf der Jefferies London Healthcare Conference präsentieren. Webcasts werden etwa 30 Tage nach den Veranstaltungen auf der Website des Unternehmens verfügbar sein.

Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in two upcoming investor conferences in November.

Stifel 2024 Healthcare Conference
Monday, November 18, 2024
5:35AM PT/8:35AM ET

Jefferies London Healthcare Conference
Wednesday, November 20, 2024
10:00AM GMT/ 5:00AM ET

Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company's website for approximately 30 days.

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.

Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factor” heading in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com


FAQ

When is Allogene Therapeutics (ALLO) presenting at the Stifel Healthcare Conference 2024?

Allogene Therapeutics (ALLO) is presenting at the Stifel Healthcare Conference on Monday, November 18, 2024, at 5:35AM PT/8:35AM ET.

What investor conferences is Allogene Therapeutics (ALLO) attending in November 2024?

Allogene Therapeutics (ALLO) is attending two investor conferences in November 2024: the Stifel Healthcare Conference on November 18 and the Jefferies London Healthcare Conference on November 20.

Where can investors watch Allogene Therapeutics' (ALLO) conference presentations?

Investors can watch the webcasts on Allogene Therapeutics' website (www.allogene.com) under the Investors tab in the News and Events section, with replays available for approximately 30 days after the events.

Allogene Therapeutics, Inc.

NASDAQ:ALLO

ALLO Rankings

ALLO Latest News

ALLO Stock Data

434.02M
145.66M
17.43%
80.25%
17.68%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SOUTH SAN FRANCISCO